HanchorBio Set to Launch IPO at NT$120, Expanding Global Reach in Biotechnology
HanchorBio, Inc. (TPEx: 7827), a prominent player in the biotechnology sector, is poised for a significant milestone with its initial public offering (IPO) set at NT$120 per share ahead of its expected listing on the Taiwan Innovation Board on May 29, 2026. This strategic move comes as the company garners substantial interest from both local and international institutional investors, leading to an oversubscribed offering that reflects a robust demand for innovative biotechnology solutions.
The share allocation includes 9.4 million new common shares that HanchorBio plans to issue during its pre-listing capital increase. Notably, 10% of these shares have been reserved for employee subscription, while the remainder, totaling 8.46 million shares, will be made available to investors through a bookbuilding process that took place from May 15 to May 19. The price was finalized at NT$120 after receiving high levels of interest.
In a noteworthy collaboration, HanchorBio has brought on OrbiMed, a leading global healthcare investment firm, as a strategic investor. This partnership highlights a growing international recognition of HanchorBio’s platform and its potential in the biotechnology landscape.
HanchorBio operates with a disciplined financial strategy, as is evident in its IPO structure, which focuses on maintaining stability and providing long-term value to its shareholders. By limiting the share capital released through this offering to about 6%, the company aims to minimize unnecessary dilution for existing investors. The results from the bookbuilding have helped expand HanchorBio’s shareholder base by attracting institutional investors, which is expected to bolster the company’s position as it approaches its public market debut.
The company is keen on leveraging OrbiMed’s investment, which underscores the recognition of its innovative FBDB™ fusion protein platform. HanchorBio’s commitment extends beyond the IPO; they are actively pursuing partnerships with pharmaceutical companies to enhance their global presence and collaborative efforts in drug development. This is particularly important as HanchorBio operates in the realm of immunotherapies for both oncology and autoimmune diseases, addressing critical unmet medical needs.
Presently, HanchorBio's financial health is strong, with approximately US$140 million in cash and accessible bank credit facilities, equivalent to around NT$4.5 billion. The company believes this financial resource will be pivotal in supporting its ongoing clinical trials, process development, and expansion of global business initiatives. HanchorBio has structured its operations to encompass early-stage research, development, and comprehensive clinical development, aligning its goals with the dynamic needs of global healthcare.
Scott Liu, Ph.D., who serves as Founder, Chairman, and CEO of HanchorBio, articulated the company’s vision amidst a shifting landscape within the global pharmaceutical industry. As prominent drugs like Keytruda approach patent expirations, there is an escalating demand for innovative solutions. HanchorBio’s advanced platform is strategically positioned to meet these needs as large pharmaceutical companies increasingly seek external innovative solutions to enhance their portfolios.
Founded in 2020, HanchorBio has quickly established itself as a key player in the biotechnology landscape, particularly focusing on immuno-oncology and immune-mediated disorders. Their proprietary Fc-based designer biologics (FBDB™) platform is at the core of their offerings, facilitating the creation of multifunctional biologics that aim to improve health outcomes through innovative engineering.
The excitement surrounding HanchorBio's IPO reflects broader trends in biotechnology as the industry moves toward innovative therapies that promise to change the treatment landscape for various diseases. As HanchorBio approaches its IPO date, stakeholders are keen to see how this emerging company will navigate the complexities of the public markets while continuing to provide cutting-edge solutions in biotechnology.
The share allocation includes 9.4 million new common shares that HanchorBio plans to issue during its pre-listing capital increase. Notably, 10% of these shares have been reserved for employee subscription, while the remainder, totaling 8.46 million shares, will be made available to investors through a bookbuilding process that took place from May 15 to May 19. The price was finalized at NT$120 after receiving high levels of interest.
In a noteworthy collaboration, HanchorBio has brought on OrbiMed, a leading global healthcare investment firm, as a strategic investor. This partnership highlights a growing international recognition of HanchorBio’s platform and its potential in the biotechnology landscape.
HanchorBio operates with a disciplined financial strategy, as is evident in its IPO structure, which focuses on maintaining stability and providing long-term value to its shareholders. By limiting the share capital released through this offering to about 6%, the company aims to minimize unnecessary dilution for existing investors. The results from the bookbuilding have helped expand HanchorBio’s shareholder base by attracting institutional investors, which is expected to bolster the company’s position as it approaches its public market debut.
The company is keen on leveraging OrbiMed’s investment, which underscores the recognition of its innovative FBDB™ fusion protein platform. HanchorBio’s commitment extends beyond the IPO; they are actively pursuing partnerships with pharmaceutical companies to enhance their global presence and collaborative efforts in drug development. This is particularly important as HanchorBio operates in the realm of immunotherapies for both oncology and autoimmune diseases, addressing critical unmet medical needs.
Presently, HanchorBio's financial health is strong, with approximately US$140 million in cash and accessible bank credit facilities, equivalent to around NT$4.5 billion. The company believes this financial resource will be pivotal in supporting its ongoing clinical trials, process development, and expansion of global business initiatives. HanchorBio has structured its operations to encompass early-stage research, development, and comprehensive clinical development, aligning its goals with the dynamic needs of global healthcare.
Scott Liu, Ph.D., who serves as Founder, Chairman, and CEO of HanchorBio, articulated the company’s vision amidst a shifting landscape within the global pharmaceutical industry. As prominent drugs like Keytruda approach patent expirations, there is an escalating demand for innovative solutions. HanchorBio’s advanced platform is strategically positioned to meet these needs as large pharmaceutical companies increasingly seek external innovative solutions to enhance their portfolios.
Founded in 2020, HanchorBio has quickly established itself as a key player in the biotechnology landscape, particularly focusing on immuno-oncology and immune-mediated disorders. Their proprietary Fc-based designer biologics (FBDB™) platform is at the core of their offerings, facilitating the creation of multifunctional biologics that aim to improve health outcomes through innovative engineering.
The excitement surrounding HanchorBio's IPO reflects broader trends in biotechnology as the industry moves toward innovative therapies that promise to change the treatment landscape for various diseases. As HanchorBio approaches its IPO date, stakeholders are keen to see how this emerging company will navigate the complexities of the public markets while continuing to provide cutting-edge solutions in biotechnology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.